ETON Eton Pharmaceuticals, Inc.

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

Eton Pharmaceuticals, Inc. (ETON) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• $14.0M upfront + 8% royalty on net sales for patent life; ~$2.2M additional inventory purchases at closing and May 2026
• Financed entirely from cash on hand; deal expected accretive to 2026 earnings

+3 more insights

Other Eton Pharmaceuticals, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Feb 25, 2026

Get deeper insights on Eton Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.